We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
126
CALL
PTC Therapeutics
PTCT
$6.17B
$2.94M 0.11%
611
+311
+104% +$18.1K
HCA icon
127
PUT
HCA Healthcare
HCA
$91B
$2.94M 0.11%
+324
New +$26K
RIBT
128
DELISTED
RiceBran Technologies
RIBT
$2.88M 0.1%
84,586
+7,456
+10% +$269K
ALXN
129
DELISTED
Alexion Pharmaceuticals
ALXN
$2.87M 0.1%
+15,895
New +$2.74M
FEIC
130
CALL
DELISTED
FEI COMPANY
FEIC
$2.82M 0.1%
+340
New +$27.1K
ASND icon
131
Ascendis Pharma A/S
ASND
$16.7B
$2.81M 0.1%
160,000
-34,023
-18% -$595K
IMUC
132
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$2.77M 0.1%
146,795
-431
-0.3% -$8.29K
CEMP
133
DELISTED
Cempra, Inc.
CEMP
$2.73M 0.1%
79,553
-120,847
-60% -$4.27M
BCLI
134
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$2.69M 0.1%
49,576
-44,393
-47% -$2.65M
AGTC
135
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.65M 0.1%
172,427
+22,427
+15% +$430K
ANAC
136
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2.63M 0.1%
+339
New +$22.2K
SGYPW
137
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$2.6M 0.1%
3,136
+1,015
+48% +$1.78K
BCRX icon
138
CALL
BioCryst Pharmaceuticals
BCRX
$2.42B
$2.57M 0.09%
1,722
+668
+63% +$7.59K
DVAX
139
PUT
DELISTED
Dynavax Technologies
DVAX
$2.57M 0.09%
+1,096
New +$23.9K
LXRX icon
140
Lexicon Pharmaceuticals
LXRX
$1.02B
$2.57M 0.09%
318,775
-448,625
-58% -$3.29M
EW icon
141
Edwards Lifesciences
EW
$48.9B
$2.54M 0.09%
+106,890
New +$2.41M
PGNX
142
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.51M 0.09%
3,369
+10
+0.3% +$61
ANIP icon
143
CALL
ANI Pharmaceuticals
ANIP
$1.84B
$2.48M 0.09%
+400
New +$23.8K
RXDX
144
DELISTED
Ignyta, Inc.
RXDX
$2.48M 0.09%
164,100
-94,932
-37% -$1.15M
XOMA
145
CALL
DELISTED
Xoma
XOMA
$2.35M 0.09%
303
+166
+121% +$12K
AM
146
CALL
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
$2.33M 0.08%
+812
New +$21.8K
GNCA
147
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.31M 0.08%
21,073
+8,573
+69% +$796K
KYNB
148
Kyntra Bio
KYNB
$28.2M
$2.31M 0.08%
3,924
+2,388
+155% +$1.39M
MDCO
149
PUT
DELISTED
Medicines Co
MDCO
$2.3M 0.08%
803
+65
+9% +$1.81K
GWPH
150
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.26M 0.08%
18,405
-34,371
-65% -$3.9M
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.